Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND
December 03 2020 - 7:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three
poster presentations at the 31st International Symposium on ALS/MND
taking place online from December 9 – December 11, 2020.
Title: A Phase 3,
Multi-Center, Double-Blind, Randomized,
Placebo Controlled Trial to Evaluate the
Efficacy and Safety of
Reldesemtiv in Patients
with Amyotrophic Lateral Sclerosis (ALS):
COURAGE-ALS Trial DesignSession: Live
Poster Session ADate: December 9, 2020Theme: 09 – Clinical Trials
and Trial DesignPresentation Time: 5:10 – 5:50 PM GMTPoster Number:
CLT-04Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead
Investigator of FORTITUDE-ALS, Professor and Chair of Neurology
at Barrow Neurological Institute, and Professor and Executive
Chair of Neurology at the University of
Arizona, Phoenix
Title: Impact of
Patient Characteristics on Effect Size in
FORTITUDE-ALSSession: Live Poster Session BDate:
December 10, 2020Theme: 09 – Clinical Trials and Trial
DesignPresentation Time: 5:10 – 5:50 PM GMTPoster Number:
CLT-17Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead
Investigator of FORTITUDE-ALS, Professor and Chair of Neurology
at Barrow Neurological Institute, and Professor and Executive
Chair of Neurology at the University of
Arizona, Phoenix
Title: People Living
with ALS and Their Caregivers’ Input into Drug
Development in EuropeSession: Live Poster Session CTheme:
13 – Clinical Management, Support and InformationDate: December 11,
2020Presentation Time: 12:05 – 12:50 PM GMTPoster Number:
CMS-33Poster Presenter: Miriam Galvin, Ph.D., Academic Unit of
Neurology, Trinity Biomedical Sciences Institute, Trinity College
Dublin
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and next-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is preparing for regulatory
interactions for omecamtiv mecarbil, its novel cardiac muscle
activator, following positive results from GALACTIC-HF, a large,
international Phase 3 clinical trial in patients with heart
failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3
clinical trial of omecamtiv mecarbil. Cytokinetics is also
developing CK-274, a next- generation cardiac myosin inhibitor, for
the potential treatment of hypertrophic cardiomyopathies (HCM).
Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of
CK-274 in patients with obstructive HCM. Cytokinetics is also
developing reldesemtiv, a fast skeletal muscle troponin activator
for the potential treatment of ALS and other neuromuscular
indications following conduct of FORTITUDE-ALS and other Phase 2
clinical trials. The company is considering potential advancement
of reldesemtiv to Phase 3 pending ongoing regulatory interactions.
Cytokinetics continues its over 20-year history of pioneering
innovation in muscle biology and related pharmacology focused to
diseases of muscle dysfunction and conditions of muscle
weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and follow
us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to the potential benefits of
reldesemtiv, including its ability to represent an additive and
complementary approach to increase muscle function; Cytokinetics’
and its partners’ research and development activities; the timing
of enrollment of patients in Cytokinetics’ and its partners’
clinical trials; the design, timing, results, significance and
utility of preclinical and clinical results; and the properties and
potential benefits of Cytokinetics’ drug candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory
approvals for trial commencement, progression or product sale or
manufacturing, or production of Cytokinetics’ drug candidates that
could slow or prevent clinical development or product approval;
patient enrollment for or conduct of clinical trials may be
difficult or delayed; Cytokinetics’ drug candidates may have
adverse side effects or inadequate therapeutic efficacy; the FDA or
foreign regulatory agencies may delay or limit Cytokinetics’ or its
partners’ ability to conduct clinical trials; and Cytokinetics may
be unable to obtain or maintain patent or trade secret protection
for its intellectual property; Astellas’ decisions with respect to
the design, initiation, conduct, timing and continuation of
development activities for reldesemtiv; standards of care may
change, rendering Cytokinetics’ drug candidates obsolete;
competitive products or alternative therapies may be developed by
others for the treatment of indications Cytokinetics’ drug
candidates and potential drug candidates may target; and risks and
uncertainties relating to the timing and receipt of payments from
its partners, including milestones and royalties on future
potential product sales under Cytokinetics’ collaboration
agreements with such partners. For further information regarding
these and other risks related to Cytokinetics’ business, investors
should consult Cytokinetics’ filings with the Securities and
Exchange Commission.
Contact:CytokineticsDiane
WeiserSenior Vice President, Corporate Communications, Investor
Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024